Professor Wainwright joins the Queensland medical research institute with a career spanning fundamental biomedical discovery, translational science and senior research leadership across Australia’s medical research sector.

Avecho chief executive Dr Paul Gavin said the timing reflected the program's growing commercial relevance as it approaches a critical clinical and regulatory stage.

Acrux has appointed physician and biopharmaceutical executive Dr Jolanta Airey as its chief medical officer, strengthening its leadership team as it prepares to advance its female testosterone treatment toward Phase 3 clinical trials in the United States.

World-renowned plastic and reconstructive surgeon, Professor Fiona Wood AO, has been announced as the Depaz Orator for the AusBiotech International Conference, held as part of Australia’s Biggest Week in Biotech on the Gold Coast in October 2026.

Telix Pharmaceuticals reported a strong first half of 2026, with double-digit revenue growth and improved margins, supported by continued investment in a late-stage radiopharmaceutical pipeline advancing toward key clinical and regulatory milestones.

Recce Pharmaceuticals has secured Australian ethics approval to expand its pivotal Phase 3 trial of RECCE 327 Topical Gel by adding a head-to-head study against antibiotics currently used to treat diabetic foot infections.

The payment, worth approximately A$14.1 million, is the first instalment under an agreement that gives Everest exclusive rights to develop and commercialise DMX-200 across Greater China, South Korea and selected Southeast Asian markets.

Medical Developments International has reported higher profitability and a sharp improvement in cash generation, with accelerating demand for Penthrox in Australia and Europe supporting a more positive outlook for the emergency pain relief specialist.

Interim chief executive and managing director Gordon Naylor said CSL took decisive action during the year to simplify the organisation, strengthen commercial capabilities, and position newer therapies for growth.

Mesoblast has completed treatment of all 350 patients in its pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain caused by inflammatory degenerative disc disease, putting the company on track for top-line results in mid-2027.

Dimerix has taken over sponsorship of a United States investigational new drug application for DMX-652, giving the Australian biotechnology company direct control of clinical development plans for its newly acquired acute kidney injury asset.

OncoSil Medical has received US Food and Drug Administration approval for its OncoSil device to treat patients with unresectable, non-metastatic distal cholangiocarcinoma, giving the Australian medical-device company a pathway into the world’s largest healthcare market.

Biotron is preparing to advance its hepatitis B drug candidate into formal preclinical development after new laboratory studies found it showed strong antiviral activity against both hepatitis B and hepatitis D viruses, including in combination with an existing treatment for hepatitis delta.

Six Australian health and medical technology startups have secured a combined $13.5 million through the second funding round of CUREator+, as the national commercialisation program seeks to move locally developed therapies, diagnostics and digital health tools closer to patients and private investment.

Perth biotechnology company Spartan Therapeutics says it plans to begin a human clinical trial in 2027 of a circular RNA platform designed to restore more youthful function in organs and tissues across the body.

CLINUVEL has identified a lead formulation from its VLRX L controlled-release injectable peptide platform and plans to progress it into further preclinical studies in the first quarter of 2027.

QIMR Berghofer researchers have created a detailed new map of the chemical signals that influence heart function, in a development that could help accelerate the discovery of new treatments for heart disease.